Table 2.
Patients, n | |
---|---|
Total number of VA patients, n (%) | 39 (100) |
| |
Preparations, n (%) | |
Abnobaviscum | 24 (61.5) |
Iscador | 8 (20.5) |
Helixor | 14 (35.9) |
Iscucin | 4 (10.3) |
| |
Application, n (%) | |
subcutaneous | 33 (84.6) |
intravenous | 18 (46.2) |
Characteristics of VA-therapy applied additionally to standard of care (n = 39). Numbers in columns do not necessarily add to 39 as patients may have received various VA combinations of preparations and applications, respectively.